Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112400 | 0.92 | PDK2 (0.48) | CTSSPDK2SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2114772 | 0.88 | CTSS (0.44) | CTSSS1PR2DGAT2USP30 | |
| SCHEMBL2113359 | 0.86 | CTSS (0.53) | CTSSSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL2610208 | 0.86 | CTSS (0.57) | CTSSSMN1; SMN2LMNA | |
| SCHEMBL2610209 | 0.81 | CTSS (0.52) | CTSSSMN1; SMN2HTT | |
| SCHEMBL2114923 | 0.79 | CHRM1 (0.44) | CTSSS1PR2DGAT2NAMPT | |
| SCHEMBL2114397 | 0.79 | CTSS (0.73) | CTSSMAPT | |
| SCHEMBL2113051 | 0.78 | CHRM1 (0.49) | CTSSSMN1; SMN2KMT2AMEN1NPSR1 | |
| SCHEMBL2610207 | 0.78 | CHRM1 (0.53) | CTSSSMN1; SMN2LMNA | |
| SCHEMBL2610210 | 0.76 | CTSS (0.49) | CTSSSMN1; SMN2KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630141-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | CTSS, CTSZ, CTSV | CTSS 1/4885PDK2 3722/4885SMN1; SMN2 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.